A pilot study of brentuximab vedotin combined with AVD chemotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma. NCT01868451
Armand P et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36(14):1428-39. Abstract
Armand P et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34(31):3733-9. Abstract
Beköz H et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience. Ann Oncol 2017;28(10):2496-502. Abstract
Bonafede M et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. Clinicoecon Outcomes Res 2018;10:629-41. Abstract
Chen R et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125-32. Abstract
Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378(4):331-44. Abstract
Connors JM et al. Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study. Proc ASH 2017;Abstract 6.
Connors JM et al. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood 2017;130(11):1375-7. Abstract
Eichenauer DA et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: Final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol 2017;18(12):1680-7. Abstract
Evens AM et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;[Epub ahead of print]. Abstract
Friedberg JW et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood 2017;130(26):2829-37. Abstract
Goodman AM et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol 2018;4(9):1237-44. Abstract
Herrera AF et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131(11):1183-94. Abstract
Hui L et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017;123(19):3763-71. Abstract
Moskowitz AJ et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: A non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16(3):284-92. Abstract
Moskowitz CH et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853-62. Abstract
Radford J et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 2015;372(17):1598-607. Abstract
Ramchandren R et al. Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. Proc ASCO 2018;Abstract 7541.
Straus DJ et al. CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018;132(10):1013-21. Abstract
Straus DJ, Cahlon O. Radiation therapy for Hodgkin lymphoma — Can it be administered more safely if necessary? JAMA Oncol 2016;2(2):169-70. Abstract
Younes A et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17(9):1283-94. Abstract